` ZNTL (Zentalis Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ZNTL
vs
S&P 500

Over the past 12 months, ZNTL has underperformed S&P 500, delivering a return of -71% compared to the S&P 500's 9% growth.

Stocks Performance
ZNTL vs S&P 500

Loading
ZNTL
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ZNTL vs S&P 500

Loading
ZNTL
S&P 500
Difference
www.alphaspread.com

Performance By Year
ZNTL vs S&P 500

Loading
ZNTL
S&P 500
Add Stock

Competitors Performance
Zentalis Pharmaceuticals Inc vs Peers

S&P 500
ZNTL
ABBV
AMGN
GILD
VRTX
Add Stock

Zentalis Pharmaceuticals Inc
Glance View

Market Cap
99.3m USD
Industry
Biotechnology

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.

ZNTL Intrinsic Value
1.27 USD
Overvaluation 8%
Intrinsic Value
Price
Back to Top